3,6-二氯-2-苯并噻吩羧酸

用途生物活性靶点体内研究 3,6-二氯-2-苯并噻吩羧酸试剂级价格

3,6-二氯-2-苯并噻吩羧酸

CAS号:34576-94-8
英文名:3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID
中文名:3,6-二氯-2-苯并噻吩羧酸
CBNumber:CB01492789
分子式:C9H4Cl2O2S
分子量:247.1
MOL File:34576-94-8.mol

3,6-二氯-2-苯并噻吩羧酸化学性质

沸点 :426.4±40.0 °C(Predicted)
密度 :1.653±0.06 g/cm3(Predicted)
储存条件 :2-8°C
溶解度 :Soluble in DMSO (up to at least 20 mg/ml)
形态 :solid
酸度系数(pKa) :2.09±0.30(Predicted)
颜色 :Off-white
稳定性 :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

3,6-二氯-2-苯并噻吩羧酸性质、用途与生产工艺

用途 3,6-二氯-2-苯并噻吩羧酸用作研究用化合物。
生物活性 BT2 是 BCKDC 激酶 (BDK) 抑制剂，IC50 值为 3.19 μM。BT2 与 BDK 的结合会触发支链 α-酮酸脱氢酶复合物 (BCKDC) 的 N 末端结构域的螺旋运动，从而导致 BDK 与 BCKDC 分离。BT2 (compound 4) 也是一种有效的选择性的 Mcl-1 抑制剂，Ki 值为 59 μM。
靶点

BDK

3.19 μM (IC ₅₀ )

Mcl-1

59 μM (Ki)

体内研究

BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart.

Animal Model:	C57BL/6J male mice (8-10-week-old)
Dosage:	20 mg/kg/day
Administration:	Intraperitoneal injection; daily; for 1 week
Result:	BCKDC activity was robustly (12.3-fold) enhanced in the heart compared with the vehicle-treated animals. Less activation was obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The protein levels of BDK in kidneys and heart were reduced to averages of 39 and 24%, respectively.